Menu

Webinar

Live and recorded scientific resources presented by industry thought leaders.

Solutions

  • Characterization of the pancreatic tumor microenvironment using novel quantitative multiplex DPS

    Dr. Dana Adel Mustafa, Assistant Professor & Group leader of the Tumor Immuno-Pathology (TIP) LaboratoryErasmus University Medical Centre, Department Pathology

    In this webinar, Dr. Dana Adel Mustafa, shares how using the GeoMx Digital Spatial Profiler (DSP) to measure PDAC tissue samples can reveal the key immune-related players that drive survival in PDAC patients.

  • Incorporation And Automation of RNAscope Technology Into Your COVID-19 Viral Pathogenesis Research

    Damian Cockfield, Global Product Manager - BOND, Leica Biosystems

    Andrea De Biase, Field Application Scientist at Advanced Cell Diagnostics, a Bio-Techne Brand

    Jyoti Phatak-Sheldon, Associate Scientist at Advanced Cell Diagnostics, a Bio-Techne Brand

    In this webinar, we will demonstrate how RNAscope technology can be used to detect viral infection and pathogenesis for research, and enhance our understanding of globally important viruses, such as SARS-CoV-2. For research labs that require high throughput and automated RNA in situ hybridization (ISH) technology on BOND RX, Bio-Techne has partnered with Leica Biosystems to deliver RNAscope® ISH automated assays.

  • It Is Time For TIME (Tumor Immune Microenvironment) In Experimental And Diagnostic Pathology

    Alexander David Borowsky, MD, Professor, Pathology and Laboratory Medicine, Center for Immunology and Infectious Disease and UC Davis Comprehensive Cancer Center

    The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high-quality specific results compared to spurious, non-specific antibody staining on tissue will be easier and allow the researcher to focus on downstream applications, such as single and multiplex IHC. This webinar will focus on the steps and challenges in antibody selection and validation to enable success and reproducibility in antibody staining in IHC.

  • Phenotyping The Tumor Microenvironment Using DNA Barcoded Multiplex Technology

    Chifei Sun, Senior Histotechnologist with GSK R&D

    Understanding the tumor microenvironment (TME) is essential for the development of effective treatments for cancer patients. Traditional multiplex IHC methods offer limited understanding of the complex TME. This is partially due to technical limitations of chromogenic dyes and fluorescent detection systems.

  • The Power of Digital Pathology in Research

    Caitriona Lyons, PhD. Product Manager, Image Analysis, Leica Biosystems, Dublin, Ireland

    Learning Objectives of this webinar are the power of digital pathology and its benefits to the AP workflow and the future of digital pathology.

  • Multiplex Detection: From Discovery to Clinical Practice

    Keith Wharton, MD PhD FCAP

    Objectives of this webinar are monoplex vs Multiplex staining, Multiplexing in research including biopharma and drug development and Pathways to clinical implementation.

  • Introduction to Immuno Oncology

    Michael Bates, MD, Oncology Strategy, Medical and Scientific Affairs, Cepheid, Sunnyvale, California, USA

    Learning Objectives of this webinar are History of Immuno-Oncology, Types of Immunotherapy, Immune Checkpoint Biomarker.

  • Morphology Driven High-Plex Spatial Analysis of Tissue Microenvironments

    Traci DeGeer, BS, HT (ASCP) HTL, QIHC, Director, Advanced Staining Innovation, Leica Biosystems

    Mathias Holpert, PhD, Senior Product Application Scientist, NanoString

    In this webinar, we will show you how the integrated workflows of the Leica BOND RX and the DSP can advance your translational research.

  • Automated Multiplex Immunofluorescence

    Traci DeGeer, BS, HT (ASCP) HTL, QIHC, Director, Advanced Staining Innovation, Leica Biosystems

    Bethany Remeniuk, PhD, Global Applications Scientist, Akoya Biosciences, Inc.

    In this webinar, we will discuss how Akoya Biosciences Phenoptics assays support quantitative mIF to overcome the limitations imposed by conventional IHC methodologies. We will also discuss how our Opal assay kits and reagents can be integrated with the Leica BOND RX to automate your staining workflow to support consistent results for high-throughput studies.

  • Multiplex Immunofluorescence Profiling of Tumor Biopsies Using UltraPlex mxIF Technology

    Marie-Louise Loupart, PhD, Image Analysis Specialist for Leica Biosystems Aperio ePathology

    Helen Snyder, PhD, Director of Preclinical Development and Strategic Partnerships Cell IDx

    An unmet need in tissue diagnostics is the ability to simultaneously detect three or more markers on a single tissue specimen, i.e. multiplexing. Unlike other immunoassays, i.e. flow cytometry, ELISA and bead assays, which solely quantify the biomarker in a sample, a multiplex immunoassay quantifies the biomarker, identifies the location of the cell in the tissue and identifies the spatial relationship of the biomarkers with respect to each other.